Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate statistically significant superiority over placebo in reducing fibromyalgia pain. These findings highlight the ongoing gap between widespread patient use of CBD for fibromyalgia and the current clinical evidence base. Clinicians should communicate this uncertainty transparently when discussing CBD as part of a fibromyalgia management plan.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides the first rigorous evidence evaluating CBD efficacy in fibromyalgia, addressing a significant gap given widespread off-label use without adequate clinical validation. The results will inform evidence-based prescribing practices for a patient population with limited pharmacologic options and high disease burden. This study establishes whether CBD represents a viable therapeutic alternative or whether current clinical enthusiasm exceeds the supporting evidence base.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This randomized controlled trial provides much-needed evidence on cannabidiol for fibromyalgia, a condition where patients often seek cannabis-based treatments out of desperation given limited conventional options. While the double-blind, placebo-controlled design strengthens confidence compared to observational reports, several factors warrant caution in interpretation: single-center recruitment may limit generalizability, the enrolled population’s baseline characteristics and concurrent medication use could influence outcomes, and we cannot assess from the abstract whether CBD demonstrated superiority over placebo or simply describe the magnitude of any effect difference. Given fibromyalgia’s complex neurobiology and high placebo response rates in pain trials, clinicians should await the full results and effect sizes before substantially shifting practice. For now, if patients are interested in CBD for fibromyalgia, counseling should remain honest about the evolving evidence base while emphasizing that multimodal management including exercise, sleep optimization, and psychological support remains foundational to care.
|